Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Delirium Secondary to Lamotrigine Toxicity

Author(s): Deborah L. Sanchez*, Adam J. Fusick, Steven R. Gunther, Michael J. Hernandez, Gregory A. Sullivan, Maria C. Catalano and Glenn Catalano

Volume 15, Issue 2, 2020

Page: [156 - 159] Pages: 4

DOI: 10.2174/1574886315666200225111057

Price: $65

Abstract

Background: Lamotrigine is a phenyltriazine medication that has been approved by the United States Food and Drug Administration as monotherapy and as an adjunctive agent for the treatment of seizure disorder. It was later approved by the FDA for the treatment of bipolar disorder. Lamotrigine is generally well tolerated by patients, but some serious symptoms can occur during treatment. These severe side effects include rashes and multi-organ failure. Lamotrigine has also been associated with the development of mental status changes, frequently when used concurrently with other medications that may impact the metabolism of lamotrigine.

Objective: To present the case of a 65-year-old man being treated with lamotrigine and valproic acid who developed mental status changes after the addition of sertraline to his medication regimen, and to compare this case to existing cases reported in the literature.

Discussion: Our case adds to the existing literature by demonstrating that patients may experience adverse medication effects despite lamotrigine levels that are normally considered to be in the therapeutic range, highlighting the importance of clinical correlation when obtaining medication levels.

Conclusion: Clinicians should use caution interpreting lamotrigine levels when working up delirium, as normal levels may not rule out the development of lamotrigine toxicity.

Keywords: Lamotrigine, toxicity, delirium, interaction, sertraline, side effects.

« Previous Next »
Graphical Abstract

[1]
López-Muñoz F, Shen WW, D’Ocon P, Romero A, Álamo C. A History of the pharmacological treatment of bipolar disorder. Int J Mol Sci 2018; 19(7): 19.
[http://dx.doi.org/10.3390/ijms19072143] [PMID: 30041458]
[2]
Bauer LA. Lamotrigine.In Applied Clinical Pharmacokinetics. 3rd ed. New York: McGraw-Hill Medical 2015; pp. 593-610.
[3]
Milosheska D, Lorber B, Vovk T, Kastelic M, Dolžan V, Grabnar I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol 2016; 82(2): 399-411.
[http://dx.doi.org/10.1111/bcp.12984] [PMID: 27096250]
[4]
Marrero-Gonzalez PC, Ruano OL, Catalano G, Catalano MC. Dystonia associated with lamotrigine therapy: A case report and review of the literature. Curr Drug Saf 2014; 9(1): 60-2.
[http://dx.doi.org/10.2174/18715249113136660060] [PMID: 24138552]
[5]
Centorino MB, Catalano G, Catalano MC. Lamotrigine induced whole body tics: A case report and literature review. Curr Drug Saf 2016; 11(2): 189-91.
[http://dx.doi.org/10.2174/1574886311207040269] [PMID: 26537524]
[6]
Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7(2): 163-5.
[http://dx.doi.org/10.1016/S1059-1311(98)80074-5] [PMID: 9627209]
[7]
Chistyakova Y, Amos J. Delirium associated with lamotrigine and fluoxetine treatment. Am J Psychiatry 2008; 165(7): 918-9.
[http://dx.doi.org/10.1176/appi.ajp.2008.08020191] [PMID: 18593793]
[8]
Mueller TH, Beeber AR. Delirium from valproic acid with lamotrigine. Am J Psychiatry 2004; 161(6): 1128-9.
[http://dx.doi.org/10.1176/appi.ajp.161.6.1128-a] [PMID: 15169707]
[9]
Hennessy MJ, Wiles CM. Lamotrigine encephalopathy. Lancet 1996; 347(9006): 974-5.
[http://dx.doi.org/10.1016/S0140-6736(96)91464-6] [PMID: 8598790]
[10]
Rocha FF. Secondary delirium due to the use of lamotrigine with abrupt increase valproic acid’s dose. Br J Psychiatry 2008; 30(1): 88.
[http://dx.doi.org/10.1590/S1516-44462008000100017] [PMID: 18373026]
[11]
Sbei M, Campellone JV. Stupor from lamotrigine toxicity. Epilepsia 2001; 42(8): 1082-3.
[http://dx.doi.org/10.1046/j.1528-1157.2001.0420081082.x] [PMID: 11554897]
[12]
Lamotrigine serum level information sheet. Available from: . www.mayomedicallaboratories.com/test-catalog/Overview/80999
[13]
Muraleedharan A, Palappallil DS, Gangadhar R, Das S. Valproate induced hyperammonemic delirium. J Clin Diagn Res 2015; 9(12): FR01-3.
[PMID: 26816916]
[14]
Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: Diagnosis, prevention and treatment. Nat Rev Neurol 2009; 5(4): 210-20.
[http://dx.doi.org/10.1038/nrneurol.2009.24] [PMID: 19347026]
[15]
Yuen AW, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33(5): 511-3.
[http://dx.doi.org/10.1111/j.1365-2125.1992.tb04079.x] [PMID: 1524964]
[16]
Abou-Khalil BW. Making sense of lamotrigine serum levels. Epilepsy Curr 2005; 5(3): 115.
[http://dx.doi.org/10.1111/j.1535-7511.2005.05303.x] [PMID: 16145619]

Rights & Permissions Print Cite
Article Metrics
69
© 2024 Bentham Science Publishers | Privacy Policy